CL2007002611A1 - Compuestos derivados de eter diarilico, antagonistas de los receptores opioides mu, kappa y delta; composicion farmaceutica; y uso para el tratamiento de la obesidad. - Google Patents

Compuestos derivados de eter diarilico, antagonistas de los receptores opioides mu, kappa y delta; composicion farmaceutica; y uso para el tratamiento de la obesidad.

Info

Publication number
CL2007002611A1
CL2007002611A1 CL200702611A CL2007002611A CL2007002611A1 CL 2007002611 A1 CL2007002611 A1 CL 2007002611A1 CL 200702611 A CL200702611 A CL 200702611A CL 2007002611 A CL2007002611 A CL 2007002611A CL 2007002611 A1 CL2007002611 A1 CL 2007002611A1
Authority
CL
Chile
Prior art keywords
diarilico
eter
kappa
obesity
antagonists
Prior art date
Application number
CL200702611A
Other languages
English (en)
Inventor
Tetteh Magnus-Aryitey R George
Original Assignee
Pfizer Products Inc Sa Organiz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38963180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007002611(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc Sa Organiz filed Critical Pfizer Products Inc Sa Organiz
Publication of CL2007002611A1 publication Critical patent/CL2007002611A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
CL200702611A 2006-09-08 2007-09-07 Compuestos derivados de eter diarilico, antagonistas de los receptores opioides mu, kappa y delta; composicion farmaceutica; y uso para el tratamiento de la obesidad. CL2007002611A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82494406P 2006-09-08 2006-09-08

Publications (1)

Publication Number Publication Date
CL2007002611A1 true CL2007002611A1 (es) 2008-03-14

Family

ID=38963180

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200702611A CL2007002611A1 (es) 2006-09-08 2007-09-07 Compuestos derivados de eter diarilico, antagonistas de los receptores opioides mu, kappa y delta; composicion farmaceutica; y uso para el tratamiento de la obesidad.

Country Status (17)

Country Link
US (1) US7618996B2 (es)
EP (1) EP2064199A1 (es)
JP (1) JP2010502688A (es)
KR (1) KR20090051778A (es)
CN (1) CN101511808A (es)
AR (1) AR062679A1 (es)
AU (1) AU2007297285A1 (es)
CA (1) CA2662766C (es)
CL (1) CL2007002611A1 (es)
GT (1) GT200700075A (es)
IL (1) IL197154A0 (es)
MX (1) MX2009002527A (es)
NO (1) NO20091052L (es)
PE (1) PE20080834A1 (es)
TW (1) TW200831074A (es)
UY (1) UY30577A1 (es)
WO (1) WO2008032156A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2152671A1 (en) 2007-05-22 2010-02-17 Prosidion Limited Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8063247B2 (en) 2007-09-07 2011-11-22 Prosidion Limited Bicyclic aryl and heteroaryl receptor modulators
EP2252581B1 (en) 2008-01-22 2012-06-20 Eli Lilly And Company Kappa selective opioid receptor antagonist
IN2012DN03846A (es) * 2009-10-30 2015-08-28 Janssen Pharmaceutica Nv
AR089771A1 (es) * 2012-01-31 2014-09-17 Lilly Co Eli Derivados de bencil sulfonamida utiles como inhibidores de mogat-2
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
CN111925325B (zh) * 2020-02-17 2021-12-17 浙江大学 一种二芳香醚类化合物的合成方法
US20220370409A1 (en) 2021-05-04 2022-11-24 Janssen Pharmaceuticals, Inc. Compositions And Methods For The Treatment Of Depression
TW202345796A (zh) 2022-03-07 2023-12-01 美商健生醫藥公司 阿替卡普蘭(aticaprant)之形式

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2171839T3 (es) 1996-09-05 2002-09-16 Lilly Co Eli Analogos de carbazol como agonistas adrenergicos selectivos de beta3.
CO5011072A1 (es) 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
SK632003A3 (en) 2000-07-13 2003-06-03 Lilly Co Eli Beta3 adrenergic agonists
US7507767B2 (en) * 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
ATE308522T1 (de) 2002-05-30 2005-11-15 Lilly Co Eli Opioidrezeptorantagonisten
CN1688577A (zh) * 2002-09-18 2005-10-26 小野药品工业株式会社 三氮杂螺[5.5]十一烷衍生物及以它为活性成分的药物
DE60321207D1 (en) 2002-09-19 2008-07-03 Lilly Co Eli Diaryläther als opioid-rezeptor antagonisten
WO2004080968A1 (en) 2003-03-07 2004-09-23 Eli Lilly And Company 6-substituted nicotinamide derivatives as opioid receptor antagonists
ATE406360T1 (de) * 2003-03-07 2008-09-15 Lilly Co Eli Antagonisten der opioidrezeptoren
US7196100B2 (en) 2003-12-12 2007-03-27 Eli Lilly And Company Opioid receptor antagonists
CN1894240A (zh) * 2003-12-22 2007-01-10 伊莱利利公司 阿片受体拮抗剂
WO2005090286A1 (en) 2004-03-12 2005-09-29 Eli Lilly And Company Opioid receptor antagonists
US7288543B2 (en) 2004-03-12 2007-10-30 Eli Lilly And Company Opioid receptor antagonists
WO2005092836A1 (en) 2004-03-15 2005-10-06 Eli Lilly And Company Opioid receptor antagonists
WO2007047397A2 (en) 2005-10-13 2007-04-26 Smithkline Beecham Corporation Phenol ethers as modulators of the opioid receptors

Also Published As

Publication number Publication date
UY30577A1 (es) 2008-05-02
AU2007297285A1 (en) 2008-03-20
GT200700075A (es) 2008-09-19
WO2008032156A1 (en) 2008-03-20
KR20090051778A (ko) 2009-05-22
US20080070887A1 (en) 2008-03-20
US7618996B2 (en) 2009-11-17
CA2662766C (en) 2011-08-09
JP2010502688A (ja) 2010-01-28
AR062679A1 (es) 2008-11-26
NO20091052L (no) 2009-04-06
EP2064199A1 (en) 2009-06-03
IL197154A0 (en) 2009-11-18
TW200831074A (en) 2008-08-01
MX2009002527A (es) 2009-03-20
CN101511808A (zh) 2009-08-19
PE20080834A1 (es) 2008-07-19
CA2662766A1 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
CL2007002611A1 (es) Compuestos derivados de eter diarilico, antagonistas de los receptores opioides mu, kappa y delta; composicion farmaceutica; y uso para el tratamiento de la obesidad.
CL2007003100A1 (es) Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria.
CL2007003202A1 (es) Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular.
CL2007002974A1 (es) Compuestos derivados de benzoimidazol; composicion farmaceutica; y uso para el tratamiento de trastornos asociados con dgat1.
CL2007003266A1 (es) Compuestos derivados de progesterona, antagonistas del receptor de progesterona; composicion farmaceutica; y uso para el tratamiento de endometriosis, miomas o tumores dependientes de hormonas.
PL2054411T3 (pl) Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne
CR10379A (es) Composiones farmaceuticas de antagonistas del anticuerpo anti-cd40.
CL2007002252A1 (es) Compuestos derivados de heterociclos de nitrogeno fusionados; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, sarcopenia, caquexia, espasmos musculares, debilidad muscular despues de o
CL2007001040A1 (es) Proceso para la preparacion de antagonista de la sustancia p derivado de acil-amino-alquilen-amida.
CL2007002972A1 (es) Compuestos derivados de imidazolona e imidazolidinona, inhibidores de la 11b-hsd1; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para el tratamiento y prevencion de diabetes, obesidad, trastornos alimentarios, disl
CL2007002920A1 (es) Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2007003784A1 (es) Compuestos derivados de 1-amino-3-fenilciclopentano, que son agonistas o antagonistas de uno o mas receptores de la familia s1p; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar la esclerosis multiple, artritis reumato
CL2007002234A1 (es) Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.
CL2007001778A1 (es) Compuestos derivados de 2-pirazinacarboxamida, antagonistas/agonistas inversos selectivos de cb1; proceso de preparacion; composiciones farmaceuticas; y uso para el tratamiento y/o profilaxis de trastornos de ingestion de comida, diabetes tipo ii y a
BRPI0615163A2 (pt) composto, composição farmacêutica, uso do composto, e, métodos de tratamento de distúrbios mediados por mglur5 e para inibição da ativação de receptores de mglur5
CL2007003591A1 (es) Compuestos derivados de sulfonamida ciclicos, inhibidores de retoma de monoamina; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de disfuncion sexual, trastorno gastrointestinal, trastorno genitourinari
CL2007002578A1 (es) Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer.
CL2013001885A1 (es) Compuestos derivados de morfina, antagonistas del receptor ipiode periferico; composicion farmaceutica; formulacion oral; y uso para reducir los efectos colaterales de la terapia opioide (div. sol. 905-08).
BRPI0716171A2 (pt) composto, composiÇço farmacÊutica e uso de um composto.
CL2007001630A1 (es) Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
CL2007002018A1 (es) Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular.
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
CL2007003803A1 (es) Compuestos derivados de sulfonamidas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer, dislipidemia, diabetes, obesidad, infeccion.
WO2008021851A3 (en) Novel compounds as antagonists or inverse agonists for opioid receptors
CL2008002708A1 (es) Compuestos derivados de azaciclilisoquinolinona e isoindolinona, antagonistas de histamina-3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuestos; y uso del compuesto para el tratamiento de un trastorno cognitivo,